Neuroenhancement in young people: Proposal for research, policy, and clinical management

AJOB Neuroscience

Volumn 1, Issue 1, 2010, Pages 3-16

  Singh, Ilina ^a   Kelleher, Kelly J ^b  

^a WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^b NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

Child and adolescent psychiatry; Neuroenhancement; Neuroethics; Ritalin; Stimulant drugs

Indexed keywords

EID: 77955421169     PISSN: 21507740     EISSN: 21507759     Source Type: Journal    
DOI: 10.1080/21507740903508591     Document Type: Article

References (96)

1. Adriani, W., R. Canese, F. Podo, and G. Laviola. 2007. H MRS-detectable metabolic brain changes and reduced impulsive behavior in adult rats exposed to methylphenidate during adolescence. Neurotoxicology and Teratology 29: 116-125.
2. Amirkhan, J. 1982. Expectancies and attributions for hyperactive and medicated hyperactive students. Journal of Abnormal Child Psychology 10: 265-276.
3. Alderson, P. 1993. Children's consent to surgery. London: Open University Press.
4. Angold, A., A. Erkanli, H. L. Egger, and E. J. Costello. 2000. Stimulant treatment for children: A community perspective. Journal of the American Academy of Child & Adolescent Psychiatry 39: 795-984.
5. Arria, A. M., K. M. Caldeira, K. E. O'Grady, K. B. Vincent, E. P. Johnson, and E. D. Wish. 2008. Nonmedical use of prescription stimulants among college students: Associations with attentiondeficit-hyperactivity disorder and polydrug use. Pharmacotherapy 28: 156-169.
6. Baker, R., and J. Streatfield. 1995. What type of general practice do patients prefer? Exploration of practice characteristics influencing patient satisfaction. British Journal of General Practice 45: 654-659.
7. Beck, T. W., T. J. Housh, R. J. Schmidt, G. O. Johnson, D. J. Housh, J. W. Coburn, and M. H. Malek. 2006. The acute effects of a caffeine-containing supplement on strength, muscular endurance and anaerobic capabilities. Journal of Strength and Conditioning Research 20: 506-510.
8. Bernstein, G., M. Carroll, R. D. Crosby, A. R. Perwien, F. S. Go, and N. I. Benowitz. 1994. Caffeine effects on learning, performance and anxiety in normal school-age children. Journal of the American Academy of Child and Adolescent Psychiatry 33: 407-415.
9. Borella, A., M. Bindra, and P. M. Whitaker-Azmitia. 1997. Role of the 5-HT1A receptor in development of the neonatal rat brain: Preliminary behavioral studies. Neuropharmacology 36: 44550.
10. Bush, S. 2006. Neurocognitive enhancement: Ethical considerations for an emerging subspecialty. Applied Psychology 13: 125-136.
11. Butler, C. C., S. Rollnick, R. Pill, F. Maggs-Rapport, and N. Stott. 1998. Understanding the culture of prescribing: Qualitative study of general practitioners' and patients' perceptions of antibiotics for sore throats. General Practice 31: 637-642.
12. Caldwell, J., J. Smith, L. Alvarado, L. Caldwell, and T. Heintz. 2004. The efficacy of modafinil for sustaining alertness and simulator flight performance in F-117 pilots during 37 hours of continuous wakefulness. U.S. Air Force Research Laboratory Technical Report AFRL-HE-BR-TR-2004-0003.
13. Chatterjee, A. 2006. The promise and predicament of cosmetic neurology. Journal of Medical Ethics 32: 110-113.
14. Cheshire, W. P., Jr. 2006. Drugs for enhancing cognition and their ethical implications: A hot new cup of tea. Expert Review of Neurotherapeutics 6: 263-266.
15. Cohen, L. S., J. M. Friedman, J. W. Jefferson, E. M. Johnson, and M. L. Weiner. 1994. A reevaluation of risk of in utero exposure to lithium. Journal of the American Medical Association 271: 146-150.
16. Daniels, N. 2000. Normal functioning and the treatmentenhancement distinction. Cambridge Quarterly 93: 309-322.
17. Donohue, J. M., E. R. Berndt, M. Rosenthal, A.M. Epstein, and R. G. Frank. 2004. Effects of pharmaceutical promotion on adherence to the treatment guidelines for depression. Medical Care 42: 1176-1185.
18. Druss, B., and R. Rosenheck. 2008. Locus ofmental health treatment in an integrated service system. Psychiatric Services 51: 890-892.
19. Elliott, R., B. J. Sahakian, K. Matthews, A. Bannerjea, J. Rimmer, and T.W. Robbins. 1997. Effects of methylphenidate on spatial working memory and planning in healthy young adults. Psychopharmacology 131: 196-206.
20. Etz, R. S., D. J. Cohen, S. H. Woolf, J. S. Holtrop, K. E. Donahue, N. F. Iasscson, K. C. Stange, R. L. Ferrer, and A. L. Olson. 2008. Bridging primary care practices and communities to promote healthy behaviors. American Journal of Preventative Medicine 35(suppl.): S390-397.
21. Farwell, R. F., Y. J. Lee, D. G. Hirtz, S. I. Sulzbacher, J. H. Ellenberg, and J. B. Nelson. 1990. Phenobarbital for febrile seizures: Effects on intelligence and on seizure recurrence. New England Journal of Medicine 322: 364-369.
22. FitzGerald, D. B., G. P. Crucian, J. B. Mielke, B. V. Shenal, D. Burks, K. B. Womack, G. Ghacibeh, V. Drago, P. S. Foster, E. Valenstein, and K. M. Heilman. 2008. Effects of donepezil on verbal memory after semantic processing in healthy older adults. Cognitive Behavioral Neurology 21: 57-64.
23. Freeman, G., and S. Richards. 1990. How much personal care in four group practices. British Medical Journal 301: 1028-1030.
24. Fukuyama, F. 2003. Our posthuman future: Consequences of the biotechnology revolution. New York: Picador.
25. Goldman, L. S., M. Genel, R. J. Bezman, and P. J. Slanetz. 1998. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. Journal of the American Medical Association 279: 1100-1107.
26. Greeley, H., B. Sahakian, J. Harris, R. Kessler, M. Gazzaniga, P. Campbell, and M. Farah. 2008. Towards responsible use of neuro enhancing drugs by the healthy. Nature. doi: 10.1038/456702a. Published online 7 December.
27. Grund, T., K. Lehmann, N. Bock, A. Rothenberger, and G. Teuchert-Nood. 2006. Influence of methylphenidate on brain development-An update of recent animal experiments. Behavioral and Brain Functions 21: 2.
28. Haldelman, G. E., and R. Quirion. 1983. Neonatal exposure to morphine increases m-opiate binding in the adult forebrain. European Journal of Pharmacology 94: 3578.
29. Hartley, L. R., S. Ungapen, I. Davie, and D. J. Spencer. 1983. The effect of beta adrenergic blocking drugs on speakers' performance and memory. British Journal of Psychiatry. 142: 512-517.
30. Heneghan, A. M., M. Mercer, and N. L. DeLeone. 2004. Will mothers discuss parenting stress and depressive symptoms with their child's pediatrician? Pediatrics 113: 460-467.
31. Hickson, G. B., W. A. Allemeier, and S. O'Connor. 1983. Concerns of mothers seeking care in private pediatric offices: Opportunities for expanding services. Pediatrics 72: 619-624.
32. Hill, H. F., and J. Engblom. 1984. Effects of pre-and postnatal haloperidol administration to pregnant and nursing rats on brain catecholamine levels in their offspring. Developmental Pharmacology and Therapeutics 7: 188-197.
33. Huskamp, H. A., J. M. Donohue, C. Koss, E. R. Berndt, and R. G. Frank. 2008. Generic entry, reformulations and promotion of SSRIs in the US. Pharmacoeconomics 26: 603-616.
34. Izquierdo, I., L. R. Bevilaqua, J. I. Rossato, R. H. Lima, J. H. Medina, and M. Cammarota. Age-dependent and age-independent human memory persistence is enhanced by delayed posttraining methylphenidate administration. Proceedings of the National Academy of Sciences USA 10549: 19504-19507.
35. Jensen, P., L. E. Arnold, J. M. Swanson, B. Vitiello, H. B. Abikoff, L. L. Greenhill, L. Hechtman, S. P. Hinshaw, W. E. Pelham, K. C. Wells, C. K. Conners, G. R. Elliot, J. N. Epstein, B. Hoza, J. S. March, B. S. G. Molina, J. H. Newcorn, J. B, Severe, T. Wigal, R. D. Gibbons, and K. Hur. 2007. 3-Year follow-up of the NIMHMTA study. Journal of the American Academy of Child and Adolescent Psychiatry 46: 989-1002.
36. Johnston, C., S. Fine, M. Weiss, J. Weiss, G. Weiss, and W. S. Freeman. 2000. Effects of stimulant medication treatment on mothers' and children's attributions for the behavior of children with attention deficit hyperactivity disorder. Journal of Abnormal Child Psychology 28: 371-382.
37. Juengst, E. 1998. What does enhancement mean? In Enhancing human traits, ed. E. Parens, 29-47. Washington, DC: Georgetown University Press.
38. Kendall, T., and L. McGoey 2007. Truth, disclosure and the influence of industry on the development of NICE guidelines: An interview with Tim Kendall. Bio Societies 2: 129-140.
39. Kim, Y., M. A. Teylan, M. Baron, A. Sands, A. C. Nairn, and P. Greengard, P. 2009. Methylphenidate-induced dendritic spine formation and 1 Fos B expression in nucleus accumbens. Proceedings of the National Academy of Sciences. Doi. 10.1073/pnas.0813179106
40. Kravitz, R. L., R. M. Epstein, M. D. Feldman, C. E. Franz, R. Azari, M. S. Wilkes, L. Hinton, and P. Franks. 2005. Influence of patients' requests for direct-to-consumer advertised antidepressants: A randomized controlled trial. Journal of the American Medical Association 293: 1995-2002.
41. Kuther, T. L. 2003. Medical decision-making and minors: Issues of consent and assent. Adolescence 38: 343-358.
42. Livingstone, S., E. van Couvering, and N. Thumim. 2005. Adult media literacy: A review of the research literature on behalf of Ofcom. Available at http://legacyreports.spectrumaudit.org.uk/advice/medialiteracy/medlitpub/medlitpubrss/aml.pdf
43. Low, K. G., and A. E. Gendaszek. 2002. Illicit use of psychostimulants among college students: A preliminary study. Psychology, Health & Medicine 7: 283-287.
44. Maher, B. 2008. Poll results: Look who's doping. Nature 452: 674-675.
45. Malacrida, C. 2004. Medicalization, ambivalence and social control: Mothers descriptions of educators and ADD/ADHD. Health: An Interdisciplinary Journal for the Social Study of Health, Illness and Medicine 8: 61-80.
46. Martins, M. R., A. Reinke, F. C. Petronilho, K. M. Gomes, F. Dal-Pizzol, and J. Quevedo. 2006. Methylphenidate treatment induces oxidative stress in young rat brain. Brain Research 1078: 189-197.
47. Mazer, C., J. Muneyyirci, K. Taheny, N. Raio, A. Borella, and P. M. Whitaker-Azmitia. 1997. Serotonin depletion during synaptogenesis leads to decreased synaptic density and learning deficits in the adult rat: Apossible model of neurodevelopmental disorders with cognitive deficits. Brain Research 760: 6873.
48. Miller, V. A., D. Drotar, and E. Kodish. 2004. Children's competence for assent and consent: A review of empirical findings. Ethics & Behavior 14: 255-295.
49. Miller, K. A., D. A. Miller, G. A. Doeksen, and P. S. Shelton. 1991. Establishing a family practice: A model to determine economic feasibility. Southern Medical Journal 84: 871-875.
50. Molina, B., S. P. Hinshaw, J. M. Swanson, et al. 2009. MTA at 8 years: Prospective follow-up of children treated for combined-type ADHD in a multisite study. Journal of the American Academy of Child and Adolescent Psychiatry 48: 484-500.
51. Mumenthaler, M. S., J. A. Yesavage, J. L. Taylor, R. O'Hara, L. Friedman, H. Lee, and H. C. Kraemer. 2003. Psychoactive drugs and pilot performance: A comparison of nicotine, donepezil and alcohol effects. Neuropsychopharmacology 28: 1366-1373.
52. Nathan, P. J., A. Baker, E. Carr, J. Earle, M. Jones, M. Nieciecki, C. Hutchison, and C. Stough. 2001. Cholinergic modulation of cognitive function in healthy subjects: Acute effects of donepezil, a cholinesterase inhibitor. Psychopharmacology: Clinical and Experimental 16: 481-483.
53. O'Rourke, M. P., B. J. O'Brien, W. L. Knez, and C. D. Paton. 2008. Caffeine has a small effect on 5-km running performance of welltrained and recreational runners. Journal of Science and Medicine in Sport 11: 231-233.
54. Olfson, M., M. J. Gameroff, S. C. Marcus, and P. S. Jensen. 2003. National trends in the treatment of attention deficit hyperactivity disorder. American Journal of Psychiatry 160: 1071-1077.
55. Olson, A. L., K. J. Kemper, K. J. Kelleher, C. S. Hammond, B. S. Zuckerman, and A. J. Dietrich. 2002. Primary care pediatricians' roles and perceived responsibilities in the identification and management of maternal depression. Pediatrics 110: 1169-1176.
56. Omtzigt, J.G.C., F. J. Los, D. E. Grobbee, L. Pijpers, M. G. J. Jahoda, H. Brandenburg, and others. 1992. The risk of spina bifida aperta in first-trimester exposure to valproate in a prenatal cohort. Neurology 42(suppl.): 119S-125S.
57. Opel, D. J., and B. Wilfond. 2009. Cosmetic surgery in childrenwith cognitive disabilities: Who benefits? Who decides? Hastings Center Report 39: 19-21.
58. Parens, E. 1998. Is better always good? The enhancement project. Hastings Center Report 28: S1-S15.
59. Parens, E. 2009. Respecting children with disabilities-And their parents. Hastings Center Report 39: 22-23.
60. Pietrzak, R. H., C. M. Mollica, P. Maruff, and P. J. Snyder. 2006. Cognitive effects of immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder. Neuroscience and Biobehavioral Reviews 30: 1225-1245.
61. Poulin, C. 2001. Medical and nonmedical stimulant use among adolescents: From sanctioned to unsanctioned use. Canadian Medical Association Journal 165: 1039-1044.
62. Pradel, V., E. Frauger, X. Thirion, E. Ronfle, V. Lapierre, A. Masut, et al. 2009. Impact of a prescriptionmonitoring program on doctorshopping for high dosage buprenorphine. Pharmacoepidemiology and Drug Safety 18: 36-43.
63. President's Council on Bioethics. 2003. Beyond therapy: Biotechnology and the pursuit of happiness. New York: Dana Press.
64. Preen, D. B., J. Calver, F. M. Sanfilippo, M. Bulsara, and C. D. Holman. 2008. Prescribing of psychostimulant medications for attention deficit hyperactivity disorder in children: Differences between clinical specialties. Medical Journal of Australia 188: 337-339.
65. Rapoport, J. L., M. S. Buchsbaum, H. Weingartner, T. P. Zahn, C. Ludlow, and E. J. Mikkelsen. 1980. Dextroamphetamine: Its cognitive and behavioral effects in normal and hyperactive boys and normal men. Archives of General Psychiatry 37: 933-943.
66. Ravelingien, A., J. Braeckman, L. Crevits, D. De Ridder, and E. Mortimer. 2009. Cosmetic neurology and the moral complicity argument. Neuroethics 2. Available at http://www.springerlink.com/content/f510l37tn47p6464.
67. Rosengarten, H., and A. J. Friedhoff. 1994. Enduring changes in dopamine receptor cells of pups from drug administration to pregnant and nursing rats. Science 203: 11335.
68. Rosa, F. W. 1991. Spina bifida in infants of women treated with carbamazepine during pregnancy. New England Journal of Medicine 324: 6747.
69. Sabin, J. E., and N. Daniels. 1994. Determining medical necessity in mental health practice. Hastings Center Report 24: 5-13.
70. Safer, D.J., J. Zito, and S. dos Reis. 2003. Concomitant psychotropic medication for youths. American Journal of Psychiatry 160: 438-449.
71. Saffer. H. 2002. Alcohol advertising and youth. Journal of Studies on Alcohol Supplement 14: 173-181.
72. Sandel, M. 2007. The case against perfection: Ethics in the age of genetic engineering. New York: Belknap.
73. Sax, L., and K. J. Kautz 2003. Who first suggests the diagnosis of attention-deficit/hyperactivity disorder? Annals of Family Medicine 1: 171-174.
74. Scheffler, R., S. Hinshaw, S. Modrek, and P. Levine. 2007. The global market for ADHD medications. Health Affairs 26: 450-457.
75. Schermer, M., I. Bolt, R. de Jongh, and B. Olivier, B. 2009. The future of psychopharmacological enhancements: Expectations and policies. Neuroethics 2: 75-87.
76. Shou, M. 1976. What happened to the lithium babies: A followup study of children born withoutmalformations. Acta Psychiatrica Scandinavica 54: 1937.
77. Silver, J. A., J. D. Hughes, R. A. Bornstein, and D. Q. Beversdorf. 2004. Effect of anxiolytics on cognitive flexibility in problem solving. Cognitive Behavioral Neurology 17: 93-97.
78. Singh, I. 2005. Will the 'real boy' please behave: Dosing dilemmas for parents of boys with ADHD. American Journal of Bioethics 53: 34-47.
79. Singh, I. 2007. Not just naughty: 50 years of stimulant drug advertising. In Medicating modern America, ed. E. Watkins and A. Toon, 131-155. New York: University Press.
80. Singh, I. 2008. Beyond polemics: Science and ethics of ADHD. Nature Reviews Neuroscience 9: 957-964.
81. Singh, I, S. Keenan, and A. Mears. 2008. The experiences of children and young people of stimulant medication for ADHD. In Attention deficit hyperactivity disorder: Full guideline for consultation, 94-98. London: National Institute for Health and Clinical Excellence.
82. Singh, I., T. Kendall, C. Taylor, M. Batty, C. Hollis, and A. Mears. In press. ADHD and stimulant drug medication: UK young people's perspectives. Child and Adolescent Mental Health.
83. Stein, M., and D. Stein. 2008. Social anxiety disorder. Lancet 371: 1115-1125.
84. Synofzik, M. 2009. Ethically justified, clinically applicable criteria for physician decision-making in psychopharmacological enhancement. Neuroethics 2: 89-102.
85. Talbot, M. 2009. Brain gain. New Yorker. Available at http://www.newyorker.com/reporting/2009/04/27/090427fafacttalbot
86. Teter, C. J., S. E. McCabe, K. LaGrange, J. A. Cranford, and C. J. Boyd. 2006. Illicit use of specific prescription stimulants among college students: Prevalence, motives and routes of administration. Pharmacotherapy 26: 1501-1510.
87. Teter, C. J., S. E. McCabe, J. A. Cranford, C. J. Boyd, and S. K. Guthrie. 2005. Prevalence and motives for illicit use of prescription stimulants in an undergraduate student sample. Journal of American College Health 53: 253-262.
88. Tysome, T. 2007. Pills provide brain boost for academics. Times Higher Education Supplement [online]. Available at http://www.timeshighereducation.co.uk/story.asp?sectioncode=26&storycode=2094802007.
89. Wilens, T. E., L. A. Adler, J. Adams, S. Sgambati, J. Rotrosen, R. Sawtelle, L. Utzinger, and S. Fusillo. 2008. Misuse and diversion of stimulants prescribed for ADHD: A systematic review of the literature. Journal of the American Academy of Child and Adolescent Psychiatry 47: 21Y31.
90. Wilens, T. E., M. Gignac, A. Swezey, M. C. Monuteaux, and J. Biederman. 2006. Characteristics of adolescents and young adults with ADHD who divert ormisuse their prescribedmedicines. Journal of the American Academy of Child and Adolescent Psychiatry 45: 408-414.
91. Wolpe, P. R. 2002. Treatment, enhancement, and the ethics of neurotherapeutics. Brain & Cognition 50: 387-395.
92. Wood, D., N. Winterbauer, P. Sloyer, E. Jobli, T. Hou, Q. McCaskill, and W. C. Livingood. 2008. A longitudinal study of a pediatric practice-based versus an agency-based model of care coordination for children and youth with special health care needs. Maternity Child Health Setember 3: 667-676.
93. Wysowski, D. 2007. Surveillance of prescription drug-related mortality using death certificate data. Drug Safety 30: 533-540.
94. Yesavage, J. A., M. S. Mumenthaler, J. L. Taylor, L. Friedman, R. O'Hara, J. Sheikh, J. Tinklenberg, and P. J. Whitehouse. 2002. Donepezil and flight simulator performance: Effects on retention of complex skills. Neurology 59: 123-125.
95. Zeiss, A., and B. Karlin. 2008. Integrating mental health and primary care services in the Department of Veterans Affairs health care system. Clinical Psychology Medical Settings 15: 73-78.
96. Zuvekas, S. H., B. Vitiello, and G. S. Norquist. 2006. Recent trends in stimulant medication use among U.S. children. American Journal of Psychiatry 163: 579-585.